Report of Foreign Issuer (6-k)
August 09 2018 - 4:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2018
Commission
File Number 001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation
of registrant’s name into English)
23
Hata’as Street
Kfar
Saba, Israel 44425
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Form 6-K (including Exhibit 99.1, Exhibit 99.2 and the statements under “Second Quarter 2018
Financial Results”, “Balance Sheet Highlights”, “Forward Looking Statements” and the accompanying
financial statements in the press release in Exhibit 99.3) are incorporated
by reference into the registrant’s Registration Statements on Form S-8 (Registration No. 333-214817, 333-220015 and 333-225003)
and on Form F-3 (Registration No. 333-219614 and 333-212432).
On
August 9, 2018, Cellect Biotechnology Ltd. (the “Company”) issued a press release entitled “Cellect Biotechnology
Ltd. Provides Corporate Update and Reports Second Quarter 2018 Financial Results”. In addition, on the same day, the Company
issued unaudited interim condensed consolidated financial statements as of June 30, 2018 together with the Company’s
Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same period.
Attached
hereto and incorporated by reference herein are the following exhibits:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Cellect
Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/
Eyal Leibovitz
|
|
|
Name:
Eyal Leibovitz
|
Date:
August 9, 2018
|
|
Title:
Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Sep 2023 to Sep 2024